Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT

The oral histone deacetylase (HDAC) inhibitor (vorinostat) is safe and results in low incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning, related donor hematopoietic cell transplantation (HCT). However, its safety and efficacy in preventing acute GVHD in setting...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Choi, Sung Won, Braun, Thomas, Henig, Israel, Gatza, Erin, Magenau, John, Parkin, Brian, Pawarode, Attaphol, Riwes, Mary, Yanik, Greg, Dinarello, Charles A., Reddy, Pavan
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2017
Matèries:
Transplantation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5639486/
https://ncbi.nlm.nih.gov/pubmed/28784598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-06-790469
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars